一项高效的疫苗临床试验:ACTG A5379 艾滋病病毒感染者乙型肝炎疫苗试验
该试验针对艾滋病病毒感染者(PWH)设计乙型肝炎疫苗研究,同时解决三个主要目标:在两种研究人群中评估疫苗应答、比较多个治疗组、并进行序贯重复显著性检验。设计通过统计学与行政效率优化使样本量减少12%,并介绍了控制I型错误与中期数据监测的方法,以及国际多中心试验中实验室免疫原性终点带来的时间滞后问题(NCT04193189)。
要点
- 试验在两种PWH人群中评估乙型肝炎疫苗的血清保护性结局。
- 对疫苗未接种者研究一种疫苗方案,对既往无应答者比较两种疫苗和两种给药方案。
- 设计优化使研究样本量减少12%,并控制多重检验的I型错误。
核心结论
- 该试验设计旨在以统计学和行政效率同时解决三个主要目标,并使样本量减少12%。
研究设计与样本
- 该试验为国际多中心疫苗临床试验(NCT04193189),在两种PWH人群中评估乙型肝炎疫苗的血清保护性结局。
- 对无已知HBV疫苗接种史的PWH研究一种疫苗方案,对既往HBV疫苗接种无应答的PWH考虑多种干预,包括两种不同疫苗和两种给药方案。
主要发现
- 试验设计需考虑多重检验的统计学问题:在同一试验中评估两种研究人群的疫苗应答、比较多个治疗组、以及中期数据监测中的序贯重复显著性检验。
- 设计优化使研究样本量减少12%。
关键数值与推荐
- 原文未报告具体的免疫原性阈值或血清保护性标准数值。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 该国际多中心试验因采用实验室-based免疫原性终点而存在时间滞后问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trial designs that address multiple questions more efficiently are desirable. When we designed a hepatitis B vaccine trial to assess seroprotective outcomes in persons with HIV (PWH), we aimed for an efficient design that addressed three primary objectives in two study populations. The study focused on: PWH who did not respond to prior HBV vaccination, and PWH with no known history of HBV vaccination. Whereas one vaccine regimen was studied in the vaccine-naïve participants, multiple interventions were considered for those with prior nonresponse, with two different vaccines and two dosing schedules. Several features of the trial design required statistical considerations related to multiple testing: (1) assessment of vaccine response in two study populations under one trial, (2) comparisons among multiple treatment arms, and (3) sequential repeated significance tests in interim data monitoring. We describe the features aimed to gain statistical and administrative efficiencies, including reduction in the study sample size of 12 %. We also describe how we controlled type I error and planned interim data monitoring, and highlight the time lag issue due to the laboratory-based immunogenicity endpoint in this international, multi-center trial (NCT04193189).
引用
- Kang M, Marks KM, Cox AL, et al. An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV. Vaccine. 2025. PMID: 40147293. doi:10.1016/j.vaccine.2025.127028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。